India's Lupin Pharmaceuticals Inc. (500257,LUPIN) on Thursday said it won the final approval from U.S. Food and Drugs Administration, or FDA, to market its anti-depressant drug, escitalopram tablets, a generic version of Forest Laboratories' lexapro tablets in the U.S.
In addition, Lupin said it was the only Asian company to achieve the distinction of being the fifth largest generics player in the U.S.
Lupin's Escitalopram Tablets will be used to treat adults and children between 12-17 years and who suffer from major depressive and anxiety disorders in adults.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.